PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) today announced that it has engaged ThinkEquity Partners LLC, to assist the Company in identifying and evaluating strategic alternatives intended to enhance the future growth potential of the Company’s pipeline and maximize shareholder value. No assurances can be given that this evaluation will lead to any specific action or transaction. Cytogen does not plan to make future comments about the status of the evaluation of strategic alternatives unless there are material developments.
